Tenofovir Disoproxil Fumarate Patent Expiration
Tenofovir Disoproxil Fumarate is used for managing chronic hepatitis B and HIV infections in both adults and pediatric patients. It was first introduced by Gilead Sciences Inc
Tenofovir Disoproxil Fumarate Patents
Given below is the list of patents protecting Tenofovir Disoproxil Fumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Viread |
US5922695 (Pediatric) | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan 25, 2018
(Expired) | Gilead Sciences Inc |
| Viread |
US5935946 (Pediatric) | Nucleotide analog composition and synthesis method |
Jan 25, 2018
(Expired) | Gilead Sciences Inc |
| Viread |
US5977089 (Pediatric) | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan 25, 2018
(Expired) | Gilead Sciences Inc |
| Viread |
US6043230 (Pediatric) | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan 25, 2018
(Expired) | Gilead Sciences Inc |
| Viread | US5922695 | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul 25, 2017
(Expired) | Gilead Sciences Inc |
| Viread | US5935946 | Nucleotide analog composition and synthesis method |
Jul 25, 2017
(Expired) | Gilead Sciences Inc |
| Viread | US5977089 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul 25, 2017
(Expired) | Gilead Sciences Inc |
| Viread | US6043230 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul 25, 2017
(Expired) | Gilead Sciences Inc |
Tenofovir Disoproxil Fumarate's Family Patents
Explore Our Curated Drug Screens
Tenofovir Disoproxil Fumarate Generic API Manufacturers
Several generic applications have been filed for Tenofovir Disoproxil Fumarate. The first generic version for Tenofovir Disoproxil Fumarate was by Teva Pharmaceuticals Usa and was approved on Mar 18, 2015. And the latest generic version is by Norvium Bioscience Llc and was approved on Feb 29, 2024.
Given below is the list of companies who have filed for Tenofovir Disoproxil Fumarate generic, along with the locations of their manufacturing plants worldwide.
1. AUROBINDO PHARMA
Aurobindo Pharma Ltd has filed for 4 different strengths of generic version for Tenofovir Disoproxil Fumarate. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG | tablet | Prescription | ORAL | AB | Jan 26, 2018 |
| 150MG | tablet | Prescription | ORAL | AB | Jan 26, 2018 |
| 200MG | tablet | Prescription | ORAL | AB | Jan 26, 2018 |
| 250MG | tablet | Prescription | ORAL | AB | Jan 26, 2018 |
Manufacturing Plant Locations New
Aurobindo Pharma's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||
| United States |
| |||||||||
2. CHARTWELL
Chartwell Life Molecules Llc has filed for 1 generic for Tenofovir Disoproxil Fumarate. Given below are the details of the strengths of this generic introduced by Chartwell.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG | tablet | Prescription | ORAL | AB | Jul 26, 2018 |
Manufacturing Plant Locations New
Chartwell's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Chartwell as present at those locations.
| Country | City | Firm Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||
3. CHARTWELL RX
Chartwell Rx Sciences Llc has filed for 1 generic for Tenofovir Disoproxil Fumarate. Given below are the details of the strengths of this generic introduced by Chartwell Rx.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG | tablet | Discontinued | ORAL | N/A | Feb 26, 2018 |
4. CIPLA
Cipla Ltd has filed for 1 generic for Tenofovir Disoproxil Fumarate. Given below are the details of the strengths of this generic introduced by Cipla.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG | tablet | Prescription | ORAL | AB | Jan 26, 2018 |
Manufacturing Plant Locations New
Cipla's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Cipla as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||
5. HETERO LABS LTD III
Hetero Labs Ltd Unit Iii has filed for 1 generic for Tenofovir Disoproxil Fumarate. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd Iii.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG | tablet | Prescription | ORAL | AB | Jan 26, 2018 |
6. MACLEODS PHARMS LTD
Macleods Pharmaceuticals Ltd has filed for 1 generic for Tenofovir Disoproxil Fumarate. Given below are the details of the strengths of this generic introduced by Macleods Pharms Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG | tablet | Prescription | ORAL | AB | Jan 26, 2018 |
7. NORVIUM BIOSCIENCE
Norvium Bioscience Llc has filed for 4 different strengths of generic version for Tenofovir Disoproxil Fumarate. Given below are the details of the strengths of this generic introduced by Norvium Bioscience.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG | tablet | Prescription | ORAL | AB | Feb 29, 2024 |
| 150MG | tablet | Discontinued | ORAL | N/A | Nov 27, 2018 |
| 200MG | tablet | Discontinued | ORAL | N/A | Nov 27, 2018 |
| 250MG | tablet | Discontinued | ORAL | N/A | Nov 27, 2018 |
8. QILU
Qilu Pharmaceutical Co Ltd has filed for 3 different strengths of generic version for Tenofovir Disoproxil Fumarate. Given below are the details of the strengths of this generic introduced by Qilu.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MG | tablet | Prescription | ORAL | AB | Mar 2, 2018 |
| 250MG | tablet | Prescription | ORAL | AB | Mar 2, 2018 |
| 300MG | tablet | Prescription | ORAL | AB | Mar 2, 2018 |
Manufacturing Plant Locations New
Qilu's manufacturing plants are situated in 1 country - China. Given below are the details of these plant locations as well as the firm names of Qilu as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China |
| |||||||||||||||
9. REYOUNG
Reyoung Corporation has filed for 1 generic for Tenofovir Disoproxil Fumarate. Given below are the details of the strengths of this generic introduced by Reyoung.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG | tablet | Prescription | ORAL | AB | Mar 2, 2023 |
10. STRIDES PHARMA
Strides Pharma Global Pte Ltd has filed for 1 generic for Tenofovir Disoproxil Fumarate. Given below are the details of the strengths of this generic introduced by Strides Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG | tablet | Prescription | ORAL | AB | Jan 26, 2018 |
Manufacturing Plant Locations New
Strides Pharma's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Strides Pharma as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
| India |
| |||||
11. TEVA PHARMS USA
Teva Pharmaceuticals Usa has filed for 4 different strengths of generic version for Tenofovir Disoproxil Fumarate. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG | tablet | Prescription | ORAL | AB | Mar 18, 2015 |
| 150MG | tablet | Prescription | ORAL | AB | Jan 26, 2018 |
| 200MG | tablet | Prescription | ORAL | AB | Jan 26, 2018 |
| 250MG | tablet | Prescription | ORAL | AB | Jan 26, 2018 |